We are monitoring the impact of COVID-19 & Recession alarm on MEA Migraine Drug Market Get in touch with us for detailed analysis Know More
Share on

Middle-East and Africa Migraine Drugs Market Research Report - Segmented By Treatment, Therapeutic Class & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA)- Industry Analysis, Size, Share, Trends and Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 3955
Pages: 133

MEA Migraine Drugs Market Size (2022 to 2027)

The size of the Migraine Drugs Market in the Middle East and Africa is valued at USD 0.38 billion in 2022. It is estimated to be growing at a CAGR of 6.264% to reach USD 0.52 billion by 2027.

Factors such as growing awareness of new drug classes and increasing incidence of migraine problems across this region are expected to drive the migraine drugs market in MEA. Besides, the calcitonin gene-linked peptide (CGRP) launch is expected to drive the growth of this industry. In MEA, among these, South Africa is likely to emerge as a key opportunity in the global migraine drugs market. Elevated demand for migraine drugs, the formation of significant players in the region, and elevated emphasis on healthcare is estimated to drive significant market growth during the forecast period. The region is also seeing increased awareness of mental health in most areas and the cost-effectiveness of medical procedures. The increasing use of cost-effective preventive medicine may fuel migraine medications globally during the forecast period.

The migraine diagnosis rate is low, around 50% for episodic migraine, and 40% for chronic migraine. The KOLs said doctors often misdiagnosed migraine patients, mistaking them for cluster or tension headaches. The greatest unmet need that remains is the lack of medical education and training, which is unlikely to be met during the forecast period. 

This research report on the MEA migraine drugs market has been segmented and sub-segmented into the following categories:

  • By Treatment: Preventive and Absorptive
  • By Therapeutic Class: Triptants, Ergots, and Others
  • By Country:  KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA

Regionally, The MEA migraine medication market is estimated to hike at a sluggish rate from 2020 to 2025. Treatments for migraine are aimed at stopping symptoms or preventing future attacks of migraine. It is a common neurovascular disease characterized by tender headaches and is usually associated with other neurological indications, such as nausea, vomiting, and painful tenderness lights and sounds. Migraine is more common in women than in men, mainly due to fluctuations in hormone levels. MEA is expected to dominate the global migraine drug market and continue this trend shortly. This strong growth is primarily due to the increasing number of people suffering from migraines and the increased public awareness of the disease in this region. Further, South Africa and Turkey are the major developing countries contributing to the global migraine drug market's growth in the MEA region. It is mainly due to the high incidence of migraine in these countries. The increasing focus on niche products and their launches and the increased penetration of new drug manufacturers will positively impact the growth of the MEA anti-migraine drugs market growth shortly.

The leading companies leading in the MEA Migraine Drugs Market profiled in the report are Winston Pharmaceuticals, Allergan, and Zogenix.NValeant, SUDA, Teva, Aegis Therapeutics, Merck, TG Therapeutics, RedHill other prominent vendors the market include AbbottAeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, Bayer, CoLucid, Eli Lilly, IntelGenx, Ethypharm, Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, AstraZeneca, Meda, Dr. Reddy's Laboratories, OptiNose, Pfizer, Pozen, Eisai, Raptor. Key players in the market are Allergan, GlaxoSmithKline, Pfizer, Endo, Impax Laboratories.


                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods  

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Treatment                  

                                5.1.1 Introduction           

                                5.1.2 Preventive              

                                5.1.3 Abortive   

                                5.1.4  Y-o-Y Growth Analysis, By Treatment         

                                5.1.5  Market Attractiveness Analysis, By Treatment       

                                5.1.6  Market Share Analysis, By Treatment        

                5.2 Therapeutic                

                                5.2.1 Introduction           

                                5.2.2 Triptents  

                                5.2.3 Ergots        

                                5.2.4 Others      

                                5.2.5 Y-o-Y Growth Analysis, By Therapeutic       

                                5.2.6 Market Attractiveness Analysis, By Therapeutic     

                                5.2.7 Market Share Analysis, By Therapeutic       

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                       By Geographical Area

                                       By Treatment

                                       By Therapeutic

                                6.1.4  Market Attractiveness Analysis     

                                       By Geographical Area

                                       By Treatment

                                       By Therapeutic

                                6.1.5  Market Share Analysis      

                                       By Geographical Area

                                       By Treatment

                                       By Therapeutic

                6.2 Middle-East                                

                6.3 Africa                            

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Allergan                       

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Endo International                  

                8.3  GlaxoSmithKline                      

                8.4 Impax                           

                8.5 Pfizer                            

                8.6 Aegis Therapeutics                  

                8.7 Alder Biopharmaceuticals                     

                8.8 Astellas                        

                8.9 AstraZeneca                               

                8.10 Aeriel BioPharma                   

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          


                a) List of Tables                

                b) List of Figures                              

  1. Middle East & Africa Migraine Drug Market, By Treatment, From 2022 - 2027 (USD  Million)
  2. Middle East & Africa Preventive Market, By Region, From 2022 - 2027 (USD  Million)
  3. Middle East & Africa abortive Market, By Region, From 2022 - 2027 (USD  Million)
  4. Middle East & Africa Migraine Drug Market, By Therapeutic, From 2022 - 2027 (USD  Million)
  5. Middle East & Africa Triptents Market, By Region, From 2022 - 2027 (USD  Million)
  6. Middle East & Africa Ergots Market, By Region, From 2022 - 2027 (USD  Million)
  7. Middle East & Africa Others Market, By Region, From 2022 - 2027 (USD  Million)
  8. Middle East Migraine Drug Market, By Treatment, From 2022 - 2027 (USD  Million)
  9. Middle East Migraine Drug Market, By Therapeutic, From 2022 - 2027 (USD  Million)
  10. Africa Migraine Drug Market, By Treatment, From 2022 - 2027 (USD  Million)
  11. Africa Migraine Drug Market, By Therapeutic, From 2022 - 2027 (USD  Million)

Please wait. . . . Your request is being processed

Related Reports




pdf excel


pdf excel powerbi




What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.

Talk to our analyst and get customised report done according to your research needs


Check if you can avail any discount. Submit your details and our team will get back to you.


Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?

Find it too expensive?

Click for Request Sample